APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biosimilars Market Outlook and Growth Opportunities 2026

22 December 2025212 pages

Choose your research edition.

Industry ResearchBiosimilars Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biosimilars market include Teva Pharmaceutical, Samsung Biologics, Novartis, Merck KgaA, Mylan, Roche, Eli Lilly, Pfizer and Gan & Lee Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilars Segment by Company

Teva Pharmaceutical

Samsung Biologics

Novartis

Merck KgaA

Mylan

Roche

Eli Lilly

Pfizer

Gan & Lee Pharmaceuticals

Biogen

Amgen

Stada Arzneimittel AG

Probiomed

JCR Pharmaceuticals

Gedeon Richter

Fresenius Kabi AG

Dr. Reddy's Laboratories

Coherus Bioscience

Chong Kun Dang

Celltrion

Boehringer Ingelheim

Biocon

Biocad

Apotex

Biosimilars Segment by Type

Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)

Recombinant Glycosylated Proteins

Biosimilars Segment by Application

Oncology

Blood Disorders

Growth Hormonal Deficiency

Chronic and Autoimmune Disorders

Others

Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilars industry.

Chapter 3: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biosimilars Industry Trends Table 2. Biosimilars Industry Drivers Table 3. Biosimilars Industry Opportunities and Challenges Table 4. Biosimilars Industry Restraints Table 5. Global Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Biosimilars Sales Volume by Company (k units) & (2021-2026) Table 8. Global Biosimilars Sales Volume Share by Company (2021-2026) Table 9. Global Biosimilars Average Price (US$/unit) of Company (2021-2026) Table 10. Global Biosimilars Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biosimilars Key Company Manufacturing Base & Headquarters Table 12. Global Biosimilars Company, Product Type & Application Table 13. Global Biosimilars Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Table 18. Significant Companies of Recombinant Glycosylated Proteins Table 19. Global Biosimilars Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Biosimilars Sales Volume by Type (2021-2026) & (k units) Table 21. Global Biosimilars Sales Volume by Type (2027-2032) & (k units) Table 22. Global Biosimilars Sales Volume Share by Type (2021-2026) Table 23. Global Biosimilars Sales Volume Share by Type (2027-2032) Table 24. Global Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Biosimilars Sales Value Share by Type (2021-2026) Table 28. Global Biosimilars Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Oncology Table 30. Significant Companies of Blood Disorders Table 31. Significant Companies of Growth Hormonal Deficiency Table 32. Significant Companies of Chronic and Autoimmune Disorders Table 33. Significant Companies of Others Table 34. Global Biosimilars Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Biosimilars Sales Volume by Application (2021-2026) & (k units) Table 36. Global Biosimilars Sales Volume by Application (2027-2032) & (k units) Table 37. Global Biosimilars Sales Volume Share by Application (2021-2026) Table 38. Global Biosimilars Sales Volume Share by Application (2027-2032) Table 39. Global Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Biosimilars Sales Value Share by Application (2021-2026) Table 43. Global Biosimilars Sales Value Share by Application (2027-2032) Table 44. Global Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Biosimilars Sales by Region (2021-2026) & (k units) Table 46. Global Biosimilars Sales Market Share by Region (2021-2026) Table 47. Global Biosimilars Sales by Region (2027-2032) & (k units) Table 48. Global Biosimilars Sales Market Share by Region (2027-2032) Table 49. Global Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Biosimilars Sales Value Share by Region (2021-2026) Table 52. Global Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Biosimilars Sales Value Share by Region (2027-2032) Table 54. Global Biosimilars Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Biosimilars Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Biosimilars Sales by Country (2021-2026) & (k units) Table 59. Global Biosimilars Sales Market Share by Country (2021-2026) Table 60. Global Biosimilars Sales by Country (2027-2032) & (k units) Table 61. Global Biosimilars Sales Market Share by Country (2027-2032) Table 62. Global Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Biosimilars Sales Value Market Share by Country (2021-2026) Table 64. Global Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Biosimilars Sales Value Market Share by Country (2027-2032) Table 66. Teva Pharmaceutical Company Information Table 67. Teva Pharmaceutical Business Overview Table 68. Teva Pharmaceutical Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Teva Pharmaceutical Biosimilars Product Portfolio Table 70. Teva Pharmaceutical Recent Development Table 71. Samsung Biologics Company Information Table 72. Samsung Biologics Business Overview Table 73. Samsung Biologics Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Samsung Biologics Biosimilars Product Portfolio Table 75. Samsung Biologics Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Novartis Biosimilars Product Portfolio Table 80. Novartis Recent Development Table 81. Merck KgaA Company Information Table 82. Merck KgaA Business Overview Table 83. Merck KgaA Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Merck KgaA Biosimilars Product Portfolio Table 85. Merck KgaA Recent Development Table 86. Mylan Company Information Table 87. Mylan Business Overview Table 88. Mylan Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Mylan Biosimilars Product Portfolio Table 90. Mylan Recent Development Table 91. Roche Company Information Table 92. Roche Business Overview Table 93. Roche Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Roche Biosimilars Product Portfolio Table 95. Roche Recent Development Table 96. Eli Lilly Company Information Table 97. Eli Lilly Business Overview Table 98. Eli Lilly Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Eli Lilly Biosimilars Product Portfolio Table 100. Eli Lilly Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Pfizer Biosimilars Product Portfolio Table 105. Pfizer Recent Development Table 106. Gan & Lee Pharmaceuticals Company Information Table 107. Gan & Lee Pharmaceuticals Business Overview Table 108. Gan & Lee Pharmaceuticals Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Gan & Lee Pharmaceuticals Biosimilars Product Portfolio Table 110. Gan & Lee Pharmaceuticals Recent Development Table 111. Biogen Company Information Table 112. Biogen Business Overview Table 113. Biogen Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Biogen Biosimilars Product Portfolio Table 115. Biogen Recent Development Table 116. Amgen Company Information Table 117. Amgen Business Overview Table 118. Amgen Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Amgen Biosimilars Product Portfolio Table 120. Amgen Recent Development Table 121. Stada Arzneimittel AG Company Information Table 122. Stada Arzneimittel AG Business Overview Table 123. Stada Arzneimittel AG Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Stada Arzneimittel AG Biosimilars Product Portfolio Table 125. Stada Arzneimittel AG Recent Development Table 126. Probiomed Company Information Table 127. Probiomed Business Overview Table 128. Probiomed Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Probiomed Biosimilars Product Portfolio Table 130. Probiomed Recent Development Table 131. JCR Pharmaceuticals Company Information Table 132. JCR Pharmaceuticals Business Overview Table 133. JCR Pharmaceuticals Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. JCR Pharmaceuticals Biosimilars Product Portfolio Table 135. JCR Pharmaceuticals Recent Development Table 136. Gedeon Richter Company Information Table 137. Gedeon Richter Business Overview Table 138. Gedeon Richter Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Gedeon Richter Biosimilars Product Portfolio Table 140. Gedeon Richter Recent Development Table 141. Fresenius Kabi AG Company Information Table 142. Fresenius Kabi AG Business Overview Table 143. Fresenius Kabi AG Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Fresenius Kabi AG Biosimilars Product Portfolio Table 145. Fresenius Kabi AG Recent Development Table 146. Dr. Reddy's Laboratories Company Information Table 147. Dr. Reddy's Laboratories Business Overview Table 148. Dr. Reddy's Laboratories Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Dr. Reddy's Laboratories Biosimilars Product Portfolio Table 150. Dr. Reddy's Laboratories Recent Development Table 151. Coherus Bioscience Company Information Table 152. Coherus Bioscience Business Overview Table 153. Coherus Bioscience Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. Coherus Bioscience Biosimilars Product Portfolio Table 155. Coherus Bioscience Recent Development Table 156. Chong Kun Dang Company Information Table 157. Chong Kun Dang Business Overview Table 158. Chong Kun Dang Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Chong Kun Dang Biosimilars Product Portfolio Table 160. Chong Kun Dang Recent Development Table 161. Celltrion Company Information Table 162. Celltrion Business Overview Table 163. Celltrion Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. Celltrion Biosimilars Product Portfolio Table 165. Celltrion Recent Development Table 166. Boehringer Ingelheim Company Information Table 167. Boehringer Ingelheim Business Overview Table 168. Boehringer Ingelheim Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 169. Boehringer Ingelheim Biosimilars Product Portfolio Table 170. Boehringer Ingelheim Recent Development Table 171. Biocon Company Information Table 172. Biocon Business Overview Table 173. Biocon Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 174. Biocon Biosimilars Product Portfolio Table 175. Biocon Recent Development Table 176. Biocad Company Information Table 177. Biocad Business Overview Table 178. Biocad Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 179. Biocad Biosimilars Product Portfolio Table 180. Biocad Recent Development Table 181. Apotex Company Information Table 182. Apotex Business Overview Table 183. Apotex Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 184. Apotex Biosimilars Product Portfolio Table 185. Apotex Recent Development Table 186. Key Raw Materials Table 187. Raw Materials Key Suppliers Table 188. Biosimilars Distributors List Table 189. Biosimilars Customers List Table 190. Research Programs/Design for This Report Table 191. Authors List of This Report Table 192. Secondary Sources Table 193. Primary Sources List of Figures Figure 1. Biosimilars Product Image Figure 2. Global Biosimilars Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biosimilars Sales (2021-2032) & (k units) Figure 5. Global Biosimilars Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Image Figure 10. Recombinant Glycosylated Proteins Image Figure 11. Global Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Biosimilars Sales Volume Share by Type (2021-2032) Figure 14. Global Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Biosimilars Sales Value Share by Type (2021-2032) Figure 17. Oncology Image Figure 18. Blood Disorders Image Figure 19. Growth Hormonal Deficiency Image Figure 20. Chronic and Autoimmune Disorders Image Figure 21. Others Image Figure 22. Global Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Biosimilars Sales Volume Share by Application (2021-2032) Figure 25. Global Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Biosimilars Sales Value Share by Application (2021-2032) Figure 28. Global Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Biosimilars Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 33. North America Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 39. South America Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Biosimilars Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Biosimilars Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  • Recombinant Glycosylated Proteins
Applications
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others
Companies covered
  • Teva Pharmaceutical
  • Samsung Biologics
  • Novartis
  • Merck KgaA
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Gan & Lee Pharmaceuticals
  • Biogen
  • Amgen
  • Stada Arzneimittel AG
  • Probiomed
  • JCR Pharmaceuticals
  • Gedeon Richter
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories
  • Coherus Bioscience
  • Chong Kun Dang
  • Celltrion
  • Boehringer Ingelheim
  • Biocon
  • Biocad
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilars Sales Value (2021-2032)
  4. 1.2.2 Global Biosimilars Sales Volume (2021-2032)
  5. 1.2.3 Global Biosimilars Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biosimilars Market Dynamics
  1. 2.1 Biosimilars Industry Trends
  2. 2.2 Biosimilars Industry Drivers
  3. 2.3 Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biosimilars Industry Restraints
3 Biosimilars Market by Company
  1. 3.1 Global Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Biosimilars Sales Volume by Company (2021-2026)
  4. 3.4 Global Biosimilars Average Price by Company (2021-2026)
  5. 3.5 Global Biosimilars Company Ranking (2024-2026)
  6. 3.6 Global Biosimilars Company Manufacturing Base and Headquarters
  7. 3.7 Global Biosimilars Company Product Type and Application
  8. 3.8 Global Biosimilars Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biosimilars Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biosimilars Market by Type
  1. 4.1 Biosimilars Type Introduction
  2. 4.1.1 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  3. 4.1.2 Recombinant Glycosylated Proteins
  4. 4.2 Global Biosimilars Sales Volume by Type
  5. 4.2.1 Global Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Biosimilars Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Biosimilars Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Biosimilars Sales Value by Type
  9. 4.3.1 Global Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Biosimilars Sales Value by Type (2021-2032)
  11. 4.3.3 Global Biosimilars Sales Value Share by Type (2021-2032)
5 Biosimilars Market by Application
  1. 5.1 Biosimilars Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Blood Disorders
  4. 5.1.3 Growth Hormonal Deficiency
  5. 5.1.4 Chronic and Autoimmune Disorders
  6. 5.1.5 Others
  7. 5.2 Global Biosimilars Sales Volume by Application
  8. 5.2.1 Global Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Biosimilars Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Biosimilars Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Biosimilars Sales Value by Application
  12. 5.3.1 Global Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Biosimilars Sales Value by Application (2021-2032)
  14. 5.3.3 Global Biosimilars Sales Value Share by Application (2021-2032)
6 Biosimilars Regional Sales and Value Analysis
  1. 6.1 Global Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilars Sales by Region: 2021-2026
  4. 6.2.2 Global Biosimilars Sales by Region (2027-2032)
  5. 6.3 Global Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biosimilars Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biosimilars Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biosimilars Sales Value by Region (2027-2032)
  9. 6.5 Global Biosimilars Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biosimilars Sales Value (2021-2032)
  12. 6.6.2 North America Biosimilars Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biosimilars Sales Value (2021-2032)
  15. 6.7.2 Europe Biosimilars Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biosimilars Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biosimilars Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biosimilars Sales Value (2021-2032)
  21. 6.9.2 South America Biosimilars Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biosimilars Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Biosimilars Country-level Sales and Value Analysis
  1. 7.1 Global Biosimilars Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biosimilars Sales by Country (2021-2032)
  4. 7.3.1 Global Biosimilars Sales by Country (2021-2026)
  5. 7.3.2 Global Biosimilars Sales by Country (2027-2032)
  6. 7.4 Global Biosimilars Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biosimilars Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biosimilars Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biosimilars Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biosimilars Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biosimilars Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Biosimilars Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Biosimilars Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Samsung Biologics
  8. 8.2.1 Samsung Biologics Company Information
  9. 8.2.2 Samsung Biologics Business Overview
  10. 8.2.3 Samsung Biologics Biosimilars Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Samsung Biologics Biosimilars Product Portfolio
  12. 8.2.5 Samsung Biologics Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Biosimilars Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Biosimilars Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck KgaA
  20. 8.4.1 Merck KgaA Company Information
  21. 8.4.2 Merck KgaA Business Overview
  22. 8.4.3 Merck KgaA Biosimilars Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck KgaA Biosimilars Product Portfolio
  24. 8.4.5 Merck KgaA Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Biosimilars Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Biosimilars Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Biosimilars Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Roche Biosimilars Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Biosimilars Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Biosimilars Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Biosimilars Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Biosimilars Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Gan & Lee Pharmaceuticals
  50. 8.9.1 Gan & Lee Pharmaceuticals Company Information
  51. 8.9.2 Gan & Lee Pharmaceuticals Business Overview
  52. 8.9.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
  54. 8.9.5 Gan & Lee Pharmaceuticals Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Biosimilars Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Biosimilars Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Biosimilars Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Biosimilars Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 Stada Arzneimittel AG
  68. 8.12.1 Stada Arzneimittel AG Company Information
  69. 8.12.2 Stada Arzneimittel AG Business Overview
  70. 8.12.3 Stada Arzneimittel AG Biosimilars Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Stada Arzneimittel AG Biosimilars Product Portfolio
  72. 8.12.5 Stada Arzneimittel AG Recent Developments
  73. 8.13 Probiomed
  74. 8.13.1 Probiomed Company Information
  75. 8.13.2 Probiomed Business Overview
  76. 8.13.3 Probiomed Biosimilars Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Probiomed Biosimilars Product Portfolio
  78. 8.13.5 Probiomed Recent Developments
  79. 8.14 JCR Pharmaceuticals
  80. 8.14.1 JCR Pharmaceuticals Company Information
  81. 8.14.2 JCR Pharmaceuticals Business Overview
  82. 8.14.3 JCR Pharmaceuticals Biosimilars Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 JCR Pharmaceuticals Biosimilars Product Portfolio
  84. 8.14.5 JCR Pharmaceuticals Recent Developments
  85. 8.15 Gedeon Richter
  86. 8.15.1 Gedeon Richter Company Information
  87. 8.15.2 Gedeon Richter Business Overview
  88. 8.15.3 Gedeon Richter Biosimilars Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Gedeon Richter Biosimilars Product Portfolio
  90. 8.15.5 Gedeon Richter Recent Developments
  91. 8.16 Fresenius Kabi AG
  92. 8.16.1 Fresenius Kabi AG Company Information
  93. 8.16.2 Fresenius Kabi AG Business Overview
  94. 8.16.3 Fresenius Kabi AG Biosimilars Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Fresenius Kabi AG Biosimilars Product Portfolio
  96. 8.16.5 Fresenius Kabi AG Recent Developments
  97. 8.17 Dr. Reddy's Laboratories
  98. 8.17.1 Dr. Reddy's Laboratories Company Information
  99. 8.17.2 Dr. Reddy's Laboratories Business Overview
  100. 8.17.3 Dr. Reddy's Laboratories Biosimilars Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
  102. 8.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 8.18 Coherus Bioscience
  104. 8.18.1 Coherus Bioscience Company Information
  105. 8.18.2 Coherus Bioscience Business Overview
  106. 8.18.3 Coherus Bioscience Biosimilars Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Coherus Bioscience Biosimilars Product Portfolio
  108. 8.18.5 Coherus Bioscience Recent Developments
  109. 8.19 Chong Kun Dang
  110. 8.19.1 Chong Kun Dang Company Information
  111. 8.19.2 Chong Kun Dang Business Overview
  112. 8.19.3 Chong Kun Dang Biosimilars Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Chong Kun Dang Biosimilars Product Portfolio
  114. 8.19.5 Chong Kun Dang Recent Developments
  115. 8.20 Celltrion
  116. 8.20.1 Celltrion Company Information
  117. 8.20.2 Celltrion Business Overview
  118. 8.20.3 Celltrion Biosimilars Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Celltrion Biosimilars Product Portfolio
  120. 8.20.5 Celltrion Recent Developments
  121. 8.21 Boehringer Ingelheim
  122. 8.21.1 Boehringer Ingelheim Company Information
  123. 8.21.2 Boehringer Ingelheim Business Overview
  124. 8.21.3 Boehringer Ingelheim Biosimilars Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Boehringer Ingelheim Biosimilars Product Portfolio
  126. 8.21.5 Boehringer Ingelheim Recent Developments
  127. 8.22 Biocon
  128. 8.22.1 Biocon Company Information
  129. 8.22.2 Biocon Business Overview
  130. 8.22.3 Biocon Biosimilars Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Biocon Biosimilars Product Portfolio
  132. 8.22.5 Biocon Recent Developments
  133. 8.23 Biocad
  134. 8.23.1 Biocad Company Information
  135. 8.23.2 Biocad Business Overview
  136. 8.23.3 Biocad Biosimilars Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Biocad Biosimilars Product Portfolio
  138. 8.23.5 Biocad Recent Developments
  139. 8.24 Apotex
  140. 8.24.1 Apotex Company Information
  141. 8.24.2 Apotex Business Overview
  142. 8.24.3 Apotex Biosimilars Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Apotex Biosimilars Product Portfolio
  144. 8.24.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilars Value Chain Analysis
  2. 9.1.1 Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilars Sales Mode & Process
  6. 9.2 Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilars Distributors
  9. 9.2.3 Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst